What happens during a C&P exam for Autoimmune Hepatitis?

Do NOT stretch, warm up, or take pain medication before your exam. The VA needs your baseline limitation. Report your WORST day. DeLuca v. Brown requires documentation of functional loss during flare-ups.

EDUCATIONAL TOOL ONLY. Not legal or medical advice. Not affiliated with the VA.

← All Condition Guides

CLAIM RECON INTEL

Autoimmune Hepatitis

Q: What are the VA rating percentages for Autoimmune Hepatitis?

Autoimmune Hepatitis (DC 7345) is rated at 0%, 20%, 40%, 60%, 100% under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced). Previous history of liver disease, currently asymptomatic.

Q: What rates 0% for Autoimmune Hepatitis under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced)?

Under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) (DC 7345), a 0% rating for Autoimmune Hepatitis requires: Previous history of liver disease, currently asymptomatic.

Q: What rates 20% for Autoimmune Hepatitis under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced)?

Under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) (DC 7345), a 20% rating for Autoimmune Hepatitis requires: Chronic liver disease with at least one of: intermittent fatigue, malaise, anorexia, hepatomegaly, or pruritus.

Q: What rates 40% for Autoimmune Hepatitis under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced)?

Under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) (DC 7345), a 40% rating for Autoimmune Hepatitis requires: Progressive chronic liver disease requiring continuous medication and causing minor weight loss and at least two of: daily fatigue, malaise, anorexia, hepatomegaly, pruritus, or arthralgia.

Q: What rates 60% for Autoimmune Hepatitis under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced)?

Under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) (DC 7345), a 60% rating for Autoimmune Hepatitis requires: Progressive chronic liver disease requiring continuous medication and causing substantial weight loss and at least two of: daily fatigue, malaise, anorexia, hepatomegaly, pruritus, or arthralgia.

Q: What rates 100% for Autoimmune Hepatitis under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced)?

Under 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) (DC 7345), a 100% rating for Autoimmune Hepatitis requires: Progressive chronic liver disease requiring use of both parenteral antiviral therapy AND parenteral immunomodulatory therapy; and for six months following discontinuance of treatment.

Q: What evidence do I need for a Autoimmune Hepatitis VA claim?

Key evidence for a Autoimmune Hepatitis claim includes: Service treatment records showing injury or complaints; Imaging (X-ray, MRI, CT); Range of motion measurements; Flare-up documentation per Sharp v. Shulkin; Buddy statements describing limitations. All evidence should document both the condition and its impact on daily functioning.

DC 7345 | 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) | 

✓ VERIFIED AGAINST 38 C.F.R.§ 4.114 (Digestive system) · reviewed 2026-05-27 · ClaimRecon Editorial Team

Autoimmune Hepatitis is rated by the U.S. Department of Veterans Affairs under DC 7345 of 38 CFR § 4.114, DC 7345 (current text per 2024-05-19 amendment; Note (3) explicitly covers autoimmune liver disease alongside Hep B/C, NASH, PBC, PSC, Wilson's, alpha-1-AT, hemochromatosis, drug-induced) across 5 severity tiers (0% / 20% / 40% / 60% / 100%). Service connection requires (1) a current diagnosis, (2) an in-service event, injury, or exposure, and (3) a medical nexus opinion linking the two under 38 C.F.R. § 3.303.

OVERVIEW

Chronic liver inflammation caused by the immune system attacking liver cells, requiring immunosuppression (typically azathioprine + prednisone, or budesonide for mild cases)

RATING CRITERIA (5 LEVELS)

Previous history of liver disease, currently asymptomatic.

20%

Chronic liver disease with at least one of: intermittent fatigue, malaise, anorexia, hepatomegaly, or pruritus.

40%

Progressive chronic liver disease requiring continuous medication and causing minor weight loss and at least two of: daily fatigue, malaise, anorexia, hepatomegaly, pruritus, or arthralgia.

60%

Progressive chronic liver disease requiring continuous medication and causing substantial weight loss and at least two of: daily fatigue, malaise, anorexia, hepatomegaly, pruritus, or arthralgia.

100%

Progressive chronic liver disease requiring use of both parenteral antiviral therapy AND parenteral immunomodulatory therapy; and for six months following discontinuance of treatment.

KEY EVIDENCE TO GATHER

-Service treatment records showing injury or complaints

-Imaging (X-ray, MRI, CT)

-Range of motion measurements

-Flare-up documentation per Sharp v. Shulkin

-Buddy statements describing limitations

-Prescription history

-Physical therapy records

-Employment impact documentation

C&P EXAM TIPS (6)

1.Do NOT stretch, warm up, or take pain medication before your exam. The VA needs your baseline limitation.

2.Report your WORST day. DeLuca v. Brown requires documentation of functional loss during flare-ups.

3.Tell the examiner about flare-ups: frequency, duration, estimated ROM loss. Sharp v. Shulkin (2017) requires estimates.

4.Request active, passive, weight-bearing, and non-weight-bearing ROM testing per Correia v. McDonald (2016).

5.If you use assistive devices (brace, cane), bring them.

6.Describe daily activity impact: work, sleep, household tasks.

Secondary Conditions Explorer

736 secondaries mapped

Calculate Your Rating

VA math + dollar impact

RELATED TOOLS

Rating Calculator Secondaries Map C&P Exam Prep PACT Act Scanner 2026 Rates

SOURCES & EDITORIAL

Rating criteria text quoted verbatim from 38 C.F.R. § 4.114 (Digestive system). Source verified 2026-05-27 by ClaimRecon Editorial Team during a regulation-text comparison against the Cornell Law CFR mirror; eCFR.gov is the authoritative government source.

→ View § 4.114 on eCFR → Cornell Law mirror → Editorial Standards → Suggest a correction

EDUCATIONAL TOOL ONLY. NOT LEGAL OR MEDICAL ADVICE.
NOT AFFILIATED WITH THE U.S. DEPARTMENT OF VETERANS AFFAIRS.
CLAIM RECON 2026

LOADING